Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease

Reuters11-12

Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer's Disease

Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease $(AD)$. The company highlighted sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery (EBDTM) program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582376069?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582376069","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease <a href=\"https://laohu8.com/S/AD\">$(AD)$</a>. The company highlighted sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery (EBDTM) program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease <a href=\"https://laohu8.com/S/AD\">$(AD)$</a>. The company highlighted sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery (EBDTM) program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABOS","symbol_name":"Acumen Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7ZRP6v:1","article_id":"2582376069","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582376069","pubTimestamp":1762951689,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease . The company highlighted sabirnetug , a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery  program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Acumen Pharmaceuticals公布针对早期阿尔茨海默病的Sabirnetug数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":0.9},"content_text":"Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer's Disease\n    \n\n        Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease $(AD)$. The company highlighted sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery (EBDTM) program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582376069","isCrawlerRequest":true}